Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database

Association of polypharmacy with clinical outcomes and healthcare utilization in older adults with cardiometabolic diseases: a retrospective cohort study

BACKGROUND

Limited knowledge exists on the association between polypharmacy among older patients diagnosed with cardiometabolic diseases and the risk of clinical outcomes and healthcare utilization.

AIM

This study aimed to estimate the impact of polypharmacy on clinical outcomes and healthcare utilization in older adults with cardiometabolic diseases.

METHOD

A retrospective cohort analysis was performed using data from the Beijing Municipal Medical Insurance Database. The study focused on polypharmacy prescribing patterns in community-dwelling adults 65 years and older with cardiometabolic diseases. Polypharmacy was defined as the use of five or more medications on the index date. The primary outcome included clinical outcomes, including hospitalizations and emergency department visits. The secondary outcome focuses on hospital utilization, specifically medication costs and length of stay.

RESULTS

The study included a cohort of 405,608 patients. Among these, the most frequently used drug classes in the polypharmacy and non-polypharmacy groups were HMG-CoA reductase inhibitors and dihydropyridines, respectively. After adjustment for covariates, polypharmacy was not associated with an increased risk of hospitalization (odds ratio [OR] 1.09, 95% confidence interval [CI] 0.95-1.26, p = 0.23) or ED visits (OR 1.28, 95% CI 0.97-1.68, p = 0.08). Similarly, no significant association was found with an increase in inpatient medication costs ($2,620.5, 95% CI $2387.3-$2894.3, p = 0.97) or length of stay (3.98 days, 95% CI 3.68-4.30 days, p = 0.79). However, polypharmacy was associated with higher medication costs in outpatient settings ($73.07, 95% CI $72-$74, p < 0.05) and ED visits ($51.2, 95% CI $44.5-$59.1, p < 0.05).

CONCLUSION

Although polypharmacy is associated with increased healthcare costs in outpatient settings and ED visits, it does not significantly increase the risk of hospitalization or ED visits when properly managed.

Number-dependent association of potentially inappropriate medications with clinical outcomes and expenditures among community-dwelling older adults: a population-based cohort study

AIM

To investigate the prevalence of potentially inappropriate medication (PIM) prescribing and its number-dependent association (PIM=1, 2, ≥3) with all-cause hospitalizations, emergency department (ED) visits, and medication expenditures in Beijing, China.

METHOD

A retrospective cohort analysis was conducted to analyze PIM prescribing in community-dwelling older adults aged ≥ 65 years within the Beijing Municipal Medical Insurance Database (data from July to September 2016). The prevalence of PIMs was estimated based on the 2015 Beers Criteria. Logistic models were utilized to investigate the associations between PIM use and all-cause hospitalizations and ED visits. Generalized linear models with the logic link and gamma distribution were used to analyze associations between PIM use and medication expenditures.

RESULTS

Among the 506,214 older adults, the prevalence of PIM was 38.07%. After adjusting for covariables, prescribing 2 and ≥3 PIMs was associated with increased risks of hospitalizations (PIM=2: OR 1.34, 95%CI: 1.22-1.47; PIM≥3: OR=1.47, 95%CI: 1.32-1.63) and ED visits (PIM=2: OR = 1.29, 95%CI 1.12-1.48; PIM≥3: OR=1.23, 95%CI: 1.04-1.44). Exposures of 2 and ≥3 PIMs were associated with higher medication expenditures for inpatient visits (PIM=2: incidence rate ratio IRR = 1.08, 95%CI 1.01-1.16; PIM≥3: IRR=1.18, 95%CI: 1.08-1.28). Vasodilators were the most frequent PIM prescribing group among patients who ended with hospitalizations or ED visits.

CONCLUSIONS

PIMs were prescribed at a high rate among community-dwelling older adults in Beijing. PIMs ≥2 were associated with increased risks of hospitalizations, ED visits, and increased inpatient medication expenditures. Effective interventions are needed to target unnecessary and inappropriate medications in older adults.